Abstract
Megestrol acetate is a synthetic progestin that has been used since the 1970s for the treatment of advanced cancer and subsequently to treat anorexia, cachexia and weight loss in AIDS patients. It has been shown that high doses or prolonged treatment with this drug may cause Cushing’s syndrome, new-onset diabetes and suppression of plasma ACTH and cortisol levels. Megestrol acetate may cause suppression of the pituitary-adrenal axis due to the affinity of this compound for the glucocorticoid receptor. Recognising the glucocorticoid-like activity of megestrol and its effects at the axis level is important for the diagnosis of sub-clinical adrenal insufficiency. We present the case of a 74-year-old woman with infiltrating ductal breast carcinoma refractory to prolonged hormonal treatment with megestrol acetate, presenting with adrenal insufficiency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pecori Giraldi F, Fatti LM, Cavagnini F (2005) Isolated corticotrophin deficiency presenting with pericardial effusion. J Endocrinol Invest 28:831–833
Ron IG, Soyfer V, Goldray D et al (2002) A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving Megestrol acetate therapy. Eur J Cancer 38:1490–1494
Subramanian S, Goker H, Kanji A, Sweeney H (1997) Clinical adrenal insufficiency in patients receiving Megestrol therapy. Arch Intern Med 157:1008–1011
Naing KK, Dewar JA, Leese GP (1999) Megestrol acetate therapy and secondary adrenal suppression. Cancer 86:1044–1049
Dowsett M, Lal A, Smith IE, Jeffcoate SL (1987) The effects of low-and high-dose medroxyprogesterone acetate on sex steroid and sex hormone-binding globulin in postmenopausal breast cancer patients. Br J Cancer 55:311–313
Rowland KM, Jett JR, Jung SH et al (1994) Phase III randomized double-blind placebo-controlled trial of cisplatin and etoposide plus Megestrol acetate/placebo in extensive stage small cell lung cancer: a North Central Cancer Treatment Group study. Proc Annu Meet Am Soc Clin Oncol 13:330. Abstract
Mann M, Koller E, Murgo A et al (1997) Glucocorticoid-like activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 157:1651–1656
Willemse PHB, Van der Ploeg E, Sleijfer DT et al (1990) A randomized comparison of Megestrol acetate and medroxyprogesterone acetate in patients with advanced breast cancer. Eur J Cancer 26:337–343
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
González Villarroel, P., Fernández Pérez, I., Páramo, C. et al. Megestrol acetate-induced adrenal insufficiency. Clin Transl Oncol 10, 235–237 (2008). https://doi.org/10.1007/s12094-008-0188-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0188-7